Advanced Cell Technology, Inc., a biotechnology company, engages in the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. The company is conducting various clinical trials for treating macular degeneration, and has a preclinical development pipeline focused on products for eye diseases, autoimmune and inflammatory diseases, and wound healing.
And now it is:[stock-tools exchange=”NASDAQ” symbol=”ACTC” image_height=”100″ image_width=”150″]